Allison Gordon, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Dermatologic symptoms and side effects
My Specialties
- Oncodermatology
Get to Know Me
I am a board-certified dermatologist who specializes in supportive oncodermatology. I treat skin, hair and nail side effects that patients encounter during their cancer treatment, including chemotherapy, immunotherapy, targeted therapy, and radiation. I also manage general dermatologic diseases while my patients are under active cancer care at MSK, and provide consultation for a wide range of skin concerns. In this role, I collaborate with medical oncologists with the goal of minimizing these side effects and improving skin-related quality of life while maintaining patients on their anticancer therapy.
In addition to seeing patients in the office, I have a robust teledermatology practice that enables select patients to be seen remotely for management of their skin concerns.
I'm a dermatologist, which is a doctor with special training in skin, hair, and nails.
- Associate Attending Physician
- Strategic Partnerships Subspecialty Liaison - Dermatology
Conditions I Treat
- Dermatologic symptoms and side effects
My Specialties
- Oncodermatology
Education
- MD, Albert Einstein College of Medicine
Residencies
- Dermatology - Montefiore Medical Center
Board Certifications
- Dermatology
Awards and Honors
- Alpha Omega Alpha Honor Society (2014)
- Chief Resident, Montefiore Medical Center (2017–2018)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Gordon sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Gu L, Mehta PP, Rao D, Rotemberg V, Capanu M, Chou J, Lin S, Sigel CS, Busam KJ, Boyce L, Gordon A, O’Reilly EM. Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes. Cancer Med. 2023 Jan;12(1):179-188. doi: 10.1002/cam4.4916. Epub 2022 Jun 6. PMID: 35666021; PMCID: PMC9844595.
Kuo AM, Gu S, Stoll J, Moy AP, Dusza SW, Gordon A, Haliasos EC, Janjigian Y, Kraehenbuehl L, Quigley EA, Chapman P, Lacouture ME, Markova A. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023 Jun;11(6):e007324. doi: 10.1136/jitc-2023-007324. PMID: 37270183; PMCID: PMC10255229.
Kuo AM, Hassoun H, Shah U, Gordon A, Hollmann TJ, Landau HJ, Lezcano C, Mailankody S, Tan CC, Lesokhin AM, Markova A. Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. Leuk Lymphoma. 2022 Sep;63(9):2233-2237. doi: 10.1080/10428194.2022.2068002. Epub 2022 May 9. PMID: 35532206; PMCID: PMC9680041.
Bang AS, Anadkat MJ, Choi JN, LeBoeuf NR, Jung JY, Markova A, Gordon A, Rossi AM, Noor SJ, Sibaud V, Lacouture ME. Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors. Am J Clin Dermatol. 2022 Jul;23(4):587-589. doi: 10.1007/s40257-022-00705-z. Epub 2022 Jul 5. PMID: 35788536; PMCID: PMC10569770.
Gordon A, Rotemberg V, Love D, Kurtansky NR, Pagel D, Mones J. Use of Asynchronous Interprofessional e-Consults in Cancer Patients During the COVID-19 Pandemic: Current and Future Role. Telemed J E Health. 2023 Feb;29(2):304-309. doi: 10.1089/tmj.2021.0531. Epub 2022 Jun 28. PMID: 35763832.
Visit PubMed for a full listing of Dr. Gordon’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Allison Gordon discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].